Cell Death and Disease (Apr 2024)

Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression

  • Zhao Cui,
  • Caifeng Li,
  • Wei Liu,
  • Mo Sun,
  • Shiwen Deng,
  • Junxian Cao,
  • Hongjun Yang,
  • Peng Chen

DOI
https://doi.org/10.1038/s41419-024-06625-6
Journal volume & issue
Vol. 15, no. 4
pp. 1 – 17

Abstract

Read online

Abstract Isochlorate dehydrogenase 1 (IDH1) is an important metabolic enzyme for the production of α-ketoglutarate (α-KG), which has antitumor effects and is considered to have potential antitumor effects. The activation of IDH1 as a pathway for the development of anticancer drugs has not been attempted. We demonstrated that IDH1 can limit glycolysis in hepatocellular carcinoma (HCC) cells to activate the tumor immune microenvironment. In addition, through proteomic microarray analysis, we identified a natural small molecule, scutellarin (Scu), which activates IDH1 and inhibits the growth of HCC cells. By selectively modifying Cys297, Scu promotes IDH1 active dimer formation and increases α-KG production, leading to ubiquitination and degradation of HIF1a. The loss of HIF1a further leads to the inhibition of glycolysis in HCC cells. The activation of IDH1 by Scu can significantly increase the level of α-KG in tumor tissue, downregulate the HIF1a signaling pathway, and activate the tumor immune microenvironment in vivo. This study demonstrated the inhibitory effect of IDH1–α-KG–HIF1a on the growth of HCC cells and evaluated the inhibitory effect of Scu, the first IDH1 small molecule agonist, which provides a reference for cancer immunotherapy involving activated IDH1.